通关藤提取物抗恶性血液系统疾病作用的实验研究
|
摘要
【目的】
探讨通关藤提取物(商品名:消癌平)抗恶性血液系统疾病作用及机制,以及通关藤提取物对正常免疫细胞及造血干细胞功能的影响。
【方法】
以0μL/mL～100μL/mL的通关藤(Marsdenia tenacissima)提取物处理Jurkat、Raji、RPMI8226、HL-60、K562细胞株1～5天,MTT法检测其对5种细胞的抑制作用;流式细胞仪检测分析细胞周期改变。检测Jurkat、Raji、RPMI8226细胞株的凋亡机制,采用Annexin V/PI双染法观察细胞形态并检测其凋亡率,JC-1染色法检测细胞线粒体跨膜电位(ΔΨm)水平;Western blot检测细胞半胱氨酸蛋白酶(Caspase)-3蛋白表达。采用MTT法检测通关藤提取物对正常、ConA及LPS诱导的人淋巴细胞增殖活性的影响,中性红法检测巨噬细胞的吞噬功能,CFU-GM半固体集落培养法检测造血干细胞的集落形成能力。
【结果】
1.通关藤提取物体外对HL-60、K562、Jurkat、Raji、KPMI8226等5种细胞株具有不同程度的增殖抑制作用。在相同作用条件下,通关藤提取物对Jurkat的抑制率较高,且呈现出剂量依赖性。通关藤提取物可诱导RPMI8226和Raji细胞阻滞在G_2期,对其他细胞无明显周期阻滞。
2.通关藤提取物体外对Jurkat、Raji、RPMI8226细胞株具有不同程度的诱导凋亡作用。Jurkat的凋亡率最高,且呈现出剂量、时间依赖性。25、50μL/mL的通关藤提取物能降低Jurkat、Raji细胞内ΔΨm,并促进其凋亡。100μL/mL的通关藤提取物也可降低RPMI8226细胞ΔΨm而诱导其凋亡。50μL/mL的通关藤提取物处理组细胞Caspase-3蛋白的表达水平较对照组无明显改变。
3.通关藤提取物体外对ConA诱导的正常淋巴细胞和LPS诱导的正常淋巴细胞有促增殖作用且呈剂量依赖性。通关藤提取物对正常巨噬细胞吞噬中性红染液的能力无明显影响。对正常骨髓/外周血造血干细胞CFU-GM形成能力没有显著影响。
【结论】
1.通关藤提取物体外对多种恶性血液病细胞株具有不同程度的增殖抑制作用。
2.通关藤提取物体外对部分淋巴细胞白血病细胞株和骨髓瘤细胞株有不同程度的诱导凋亡作用,可能是通过线粒体途径诱导这些细胞凋亡。
3.通关藤提取物体外对正常免疫细胞和造血干细胞无明显的细胞毒作用,并且有促进T、B细胞增殖作用。
【Objective】To investigate the effect of anti-hematological malignances and its mechanisms of extracts from Marsdenia tenacissima(trade name:Xiao aiping),and the effect of extracts from Marsdenia tenacissima on normal human immunocytes and hemopoietic stem cells(HSCs).
【Methods】MTT method was adopted to observe the inhibiting effect of extracts from Marsdenia tenacissima with 0μL/mL～100μL/mL on Jurkat、Raji、RPMI8226、HL-60、K562 cell lines for 1～5 days.Cell cycle was detected by flow cytometry(FCM).Cell morphology and apoptosis were measured by Annexin V/PI staining and mitochondrial membrane potential(ΔΨm) was measured by JC-1 assay.Western blot method was used to detect the protein expression of caspase-3.Cell proliferation was measured by MTT assay in normal cells and cells treated with ConA or LPS.Phagocytosis of normal macrophage was measured by the dose of Neutral Red Dye.CFU-GM was assessed by semi-solid culture assay for determination of colony formation capacity of HSCs.
【Results】
1.Extracts from Marsdenia tenacissima had the most significant inhibition on Jurkat cells with dose-dependent among Jurkat,Raji,RPMI8226,HL-60,K562 cell lines in vitro. Extracts from Marsdenia tenacissima could induce G_2 phase arrest of RPMI8226 and Raji cell lines.
2.Extracts from Marsdenia tenacissima had varying degrees of apoptosis induction on Jurkat、Raji、RPMI8226 cell lines in vitro.The apoptosis rate of Jurkat cells was the highest with dose-,time- dependent.Extracts from Marsdenia tenacissima with 25 and 50μL/mL could decrease cellΔΨm and induce apoptosis in Jurkat and Raji cells,while extracts from Marsdenia tenacissima with 100μL/mL could also decrease cellΔΨm and induce apoptosis in RPMI8226 cells.No significant changes in protein expressions of caspase-3 in groups treated by extracts from Marsdenia tenacissima.
3.Extracts from Marsdenia tenacissima could enhance proliferation of normal lymphocytes treated with ConA or LPS with dose-dependent in vitro.There was no effect of extracts from Marsdenia tenacissima on macrophage to ingest Neutral Red Dye and CFU-GM colony formation capacity of normal bone marrow/ peripheral HSCs.
【Conclusion】
1.Extracts from Marsdenia tenacissima have varying degrees of inhibition on various hematological malignance cell lines in vitro.
2.Extracts from Marsdenia tenacissima induce apoptosis on some lymphocytic leukemic cell strains and myeloma cell strain in vitro by mitochondrial pathway.
3.There is no significant cell toxicity of extracts from Marsdenia tenacissima on normal immunocytes and HSCs in vitro.And extracts from Marsdenia tenacissima can enhance proliferation of normal lymphocytes treated with ConA or LPS in vitro.
探讨通关藤提取物(商品名:消癌平)抗恶性血液系统疾病作用及机制,以及通关藤提取物对正常免疫细胞及造血干细胞功能的影响。
【方法】
以0μL/mL～100μL/mL的通关藤(Marsdenia tenacissima)提取物处理Jurkat、Raji、RPMI8226、HL-60、K562细胞株1～5天,MTT法检测其对5种细胞的抑制作用;流式细胞仪检测分析细胞周期改变。检测Jurkat、Raji、RPMI8226细胞株的凋亡机制,采用Annexin V/PI双染法观察细胞形态并检测其凋亡率,JC-1染色法检测细胞线粒体跨膜电位(ΔΨm)水平;Western blot检测细胞半胱氨酸蛋白酶(Caspase)-3蛋白表达。采用MTT法检测通关藤提取物对正常、ConA及LPS诱导的人淋巴细胞增殖活性的影响,中性红法检测巨噬细胞的吞噬功能,CFU-GM半固体集落培养法检测造血干细胞的集落形成能力。
【结果】
1.通关藤提取物体外对HL-60、K562、Jurkat、Raji、KPMI8226等5种细胞株具有不同程度的增殖抑制作用。在相同作用条件下,通关藤提取物对Jurkat的抑制率较高,且呈现出剂量依赖性。通关藤提取物可诱导RPMI8226和Raji细胞阻滞在G_2期,对其他细胞无明显周期阻滞。
2.通关藤提取物体外对Jurkat、Raji、RPMI8226细胞株具有不同程度的诱导凋亡作用。Jurkat的凋亡率最高,且呈现出剂量、时间依赖性。25、50μL/mL的通关藤提取物能降低Jurkat、Raji细胞内ΔΨm,并促进其凋亡。100μL/mL的通关藤提取物也可降低RPMI8226细胞ΔΨm而诱导其凋亡。50μL/mL的通关藤提取物处理组细胞Caspase-3蛋白的表达水平较对照组无明显改变。
3.通关藤提取物体外对ConA诱导的正常淋巴细胞和LPS诱导的正常淋巴细胞有促增殖作用且呈剂量依赖性。通关藤提取物对正常巨噬细胞吞噬中性红染液的能力无明显影响。对正常骨髓/外周血造血干细胞CFU-GM形成能力没有显著影响。
【结论】
1.通关藤提取物体外对多种恶性血液病细胞株具有不同程度的增殖抑制作用。
2.通关藤提取物体外对部分淋巴细胞白血病细胞株和骨髓瘤细胞株有不同程度的诱导凋亡作用,可能是通过线粒体途径诱导这些细胞凋亡。
3.通关藤提取物体外对正常免疫细胞和造血干细胞无明显的细胞毒作用,并且有促进T、B细胞增殖作用。
【Objective】To investigate the effect of anti-hematological malignances and its mechanisms of extracts from Marsdenia tenacissima(trade name:Xiao aiping),and the effect of extracts from Marsdenia tenacissima on normal human immunocytes and hemopoietic stem cells(HSCs).
【Methods】MTT method was adopted to observe the inhibiting effect of extracts from Marsdenia tenacissima with 0μL/mL～100μL/mL on Jurkat、Raji、RPMI8226、HL-60、K562 cell lines for 1～5 days.Cell cycle was detected by flow cytometry(FCM).Cell morphology and apoptosis were measured by Annexin V/PI staining and mitochondrial membrane potential(ΔΨm) was measured by JC-1 assay.Western blot method was used to detect the protein expression of caspase-3.Cell proliferation was measured by MTT assay in normal cells and cells treated with ConA or LPS.Phagocytosis of normal macrophage was measured by the dose of Neutral Red Dye.CFU-GM was assessed by semi-solid culture assay for determination of colony formation capacity of HSCs.
【Results】
1.Extracts from Marsdenia tenacissima had the most significant inhibition on Jurkat cells with dose-dependent among Jurkat,Raji,RPMI8226,HL-60,K562 cell lines in vitro. Extracts from Marsdenia tenacissima could induce G_2 phase arrest of RPMI8226 and Raji cell lines.
2.Extracts from Marsdenia tenacissima had varying degrees of apoptosis induction on Jurkat、Raji、RPMI8226 cell lines in vitro.The apoptosis rate of Jurkat cells was the highest with dose-,time- dependent.Extracts from Marsdenia tenacissima with 25 and 50μL/mL could decrease cellΔΨm and induce apoptosis in Jurkat and Raji cells,while extracts from Marsdenia tenacissima with 100μL/mL could also decrease cellΔΨm and induce apoptosis in RPMI8226 cells.No significant changes in protein expressions of caspase-3 in groups treated by extracts from Marsdenia tenacissima.
3.Extracts from Marsdenia tenacissima could enhance proliferation of normal lymphocytes treated with ConA or LPS with dose-dependent in vitro.There was no effect of extracts from Marsdenia tenacissima on macrophage to ingest Neutral Red Dye and CFU-GM colony formation capacity of normal bone marrow/ peripheral HSCs.
【Conclusion】
1.Extracts from Marsdenia tenacissima have varying degrees of inhibition on various hematological malignance cell lines in vitro.
2.Extracts from Marsdenia tenacissima induce apoptosis on some lymphocytic leukemic cell strains and myeloma cell strain in vitro by mitochondrial pathway.
3.There is no significant cell toxicity of extracts from Marsdenia tenacissima on normal immunocytes and HSCs in vitro.And extracts from Marsdenia tenacissima can enhance proliferation of normal lymphocytes treated with ConA or LPS in vitro.
引文
1.陈信义,周霭祥.中西医结合临床血液病手册(第1版)[M].北京:中医古籍出版社,2001.
2.刘峰,麻柔.中西医临床血液病学(第1版)[M].北京:中国医药科技出版社,1998:244.
3.孙伟正,刘丽波,孙凤.中医血液病学(第1版)[M].北京:中国医药科技出版社,2000:104.
4.王东生,刘北忠.中药及其有效成分抗白血病的分子机制[J].国际中医中药杂志,2007,29(3):160-163.
5.唐由君.传统抗癌中成药配合中药复方治疗白血病的研究[J].中国中西医结合杂志,1998,18(10):583-584.
6.范先基,李俊,王志祥.王三虎治疗白血病的经验[J].广西中医药,2007,30(5):42-43.
7.邓有安,杨才明,谢波.活血化瘀中药联合化疗治疗急性白血病20例临床观察[J】.中国医药科技,2000,7(2):110-111
8.付亚玲,陈涛.中医药治疗白血病的研究现状[J].中西医结合学报,2008,6(8):867-872.
9.Yan C,Jamaluddin MS,Aggarwal B,et al.Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin[J].Mol Cancer Ther,2005,4(2):233-241.
10.王国俊,周黎明,王莉,等.三七皂甙R1诱导HL-60细胞凋亡的初步研究[J].四川生理科学杂志,2004,26(1):14-16.
11.陈婷梅,祝彼得.抗白血病中药及天然药物的研究现状[J].中国中西医结合杂志,1995,15(5):317-320.
12.花宝金.中药有效单体对肿瘤细胞诱导分化及凋亡的机制研究[J].中国中医基础医学杂志,2002,8(7):63-65.
13.Chen Y Y,Chang H M.Antiproliferative and differentiating effects of polysaccharide fraction from Fu-ling(Poria cocos) on human leukemic U937 and HL-60 cells[J].Food Chem Toxicol,2004,42(5):759-769.
14.张永清,黄高,刘红娟,等.苦参碱诱导K562细胞分化方向的研究[J].肿瘤学杂志,2004,10(1):25-27.
15.张谨,张洵,王永泉,等.藤黄酸对肿瘤细胞诱导分化作用的探讨[J].实用癌症杂志,2003,18(1):9-10.
16.陆羡,向金峰.β-榄香烯对K562细胞周期与细胞凋亡的影响及其机制探讨[J].中国小儿血液与肿瘤杂志,2008,13(4):149-152.
17.曲宝玺,纪运中,章萍,等.藤黄Ⅱ号对白血病L1210细胞杀伤动力学研究Ⅰ-显微分光光度计观察[J].中国肿瘤临床,1991(1):53-56.
18.林玲,吴周环,龚帧.中医药诱导分化白血病细胞凋亡研究进展[J].九江医学,2003,18(3):181-183.
19.王振义.开展砷剂治疗白血病的临床和机制的研究[J].中华血液学杂志,1996,7(2):57.
20.凌昌全,俞超芹,潘瑞萍,等.人参皂甙对人T淋巴细胞白血病细胞株凋亡基因的影响[J】.中医杂志,2000,41(3):176-177.
21.Suzuki K,Adachi R,Hirayama A,et al.Indirubin,a chinese anti-leukaemia drug,promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells[J].Br J Haematol,2005,130(5):681-690.
22.Tao Z,Zhou Y,Lu J,et al.Caspase-8 preferentially senses the apoptosis-inducing action of NG-18,a gmbogic acid derivative,in human leukemia HL-60 cells[J].Cancer Biol Ther,2007,6(5):691-696.
23.Liu J J,Wu X Y,Peng J,et al.Antiproliferation effects of oridonin on HL-60 cells[J].Ann Hematol,2004,83(11):691-695.
24.Liu J J,Huang R W,Lin D J,et al.Apoptotic effect of oridonin on NB4 cells and its mechanism [J].Leuk Lymphoma,2005,46(4):593-597.
25.Liu J J,Huang R W,Lin D J,et al.Oridonin-induced apoptosis in leukemia K562 cells and its mechanism[J].Neoplasma,2005,52(3):225-230.
26.高娜,茆俊卿,张育.中药逆转白血病多药耐药的研究进展[J].江苏中医药,2007,39(3):60-62.
27.谢长生,周维顺,冯正权,等.复方三根制剂对MDR细胞株K562/ADR和K562/VCR逆转作用的研究[J].中国实验方剂学杂志,2003,9(4):26-30.
28.高勇,王杰军,许青,等.人参皂甙Rg3抑制肿瘤新生血管形成机制研究[J】.肿瘤防治研究,2001,28(3):179-181.
29.姜晓玲.薏苡仁注射液对血管生成的影响[J】.肿瘤,2000,20(4):313.
30.Sohn K H,Lee H Y,Chung H Y,et al.Anti-angiogenesis activity of t riterpene acids[J].Cancer Lett,1995,94(2):213-217.
31.丁志山,高承贤,陈铌铍,等.姜黄素具有抑制血管生成与诱导肿瘤细胞凋亡双重作用[J】.中国药理学通报,2003,19(2):171-173.
32.陈志炉,史亦谦.中药诱导白血病细胞凋亡的研究近况[J].实用中西医结合临床,2007,7(3):91-93.
33.肖静云.免疫与正邪学说关系浅释[J].长春中医学院学报,2004,20(2):6.
34.马武开.中医药防治白血病的思路及方法[J].中国中医药信息杂志,2004,11(3):229-230
35.周锋,秦健,朱建中,等.莲必治注射液(穿心莲内酯)对免疫功能的调节作用(英文)[J】.南京医科大学学报(英文版),2004,18(1):40-43.
36.周金黄,刘干中.免疫药理学进展—基础与临床[M].北京:中国科学基础出版社,1993:367.
37.尹龙,徐亮,胡格,等.抗肿瘤中药及其有效成分的作用研究现状[J].动物医学进展,2006,27(1):39-43.
38.蔡文娥,杨斌.中药调节核因子-κB信号转导通路的研究进展[J].时珍国医国药,2006,17(9):1794-1796.
39.温志震,于宝海,魏虎来,等.白藜芦醇诱导K562细胞凋亡过程中Bcl-2蛋白水平的改变[J].中国临床药理学与治疗学,2006,11(4):421-423.
40.王甦,刘云鹏,候科佐,等.蟾蜍灵在诱导K562细胞凋亡过程中下调TOPO-Ⅱα蛋白表达[J].中华肿瘤防治杂志,2006,13(22):1701-1703.
41.刘加军,潘祥林,伍新尧,等.冬凌草甲素对Raji细胞的增殖抑制作用及其机制[J].中草药,2004,35(7):774-777.
42.王旭光,陈根殷,方琦.大蒜素对HL-60细胞端粒酶活性的影响.贵州医药,2004,28(4):303-305.
43.江苏新医学院.中药大辞典·下册[M].上海:上海人民出版社,1977:1976.
44.刘凤梧.中药学[M】.济南:山东科学技术出版社,1981:758.
45.蔡永敏.中药药名辞典[M].北京:中国医药出版社,1996:287
46.张民庆,龚惠明.抗癌中药的临床应用[M】.北京:人民卫生出版社,1998:100-101.
47.李红岩,王威,董方言.通光藤化学成分和药理作用研究进展[J】_中草药,2007,38(7):1101-1104.
48.Deng Jun,Liao Zhixin,Chen Dzofeng.Marsdenosides A-H,polyoxypregnane glycosides from Marsdenia Tenacissima.Phytochemistry,2005,66:1040-1051.
49.Luo Siqi,Long Longze,Geoffrey A.Polyoxypregnanes from Marsdenia Tenacissima. Phytochemistry,1993,34(6):1620-1651.
50.Shuji Miyakawa,Kimiko Yamaura,Koji Hayashi,et al.Five glycosides from the Chinese Drug "TONG-GUAN-TENG" the stem of Marsdenia Tenacissima.Phytochemistry,1986,25(12):2861-2865.
51.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J】.上海中医药杂志,2000,7(1):12-14.
52.李茂全,沈建华,胥彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
53.孙珏,沈建华,朱美华,等.消癌平对人胃癌细胞治疗作用的实验研究[J】.上海中医药大学学报,2000,14(2):41-43.
54.周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1):57-58.
55.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J】.中国民间疗法,2003,11(6):48.
56.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J】.上海医药,1996,(6):12-13.
57.孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J】.上海中医药杂志,2000,31(1):14-17.
58.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J】.现代中西医结合杂志,2004,13(20):2690-2691.
59.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J】.中国中西医结合杂志,2003,23(1):19-21.
60.赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸医学高等专科学校学报,2005.18(5):415-416.
61.杨岷,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J】.中医研究,2000,13(1):39-41.
62.赵晓民,侯伟,闫金玉,等.消癌平注射液治疗急性白血病6例[J】.中国中医急症,2007,16(1):105.
63.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J】.中国生化药 物杂志,2007,28(4):247-250.
64.李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J].中国生化药物杂志,2008,29(1):33-37.
65.李东,欧阳建,李翠萍,等.通关藤对U937细胞凋亡相关基因表达谱的影响[J】.中国生化药物杂志,2008,29(4):240-243.
1.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J】.上海中医药杂志,2000,7(1):12-14.
2.李茂全,沈建华,胥彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J】.介入放射学杂志,2001,10(4):228-231.
3.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48.
4.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J】.上海医药,1996,(6):12-13.
5.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J】.现代中西医结合杂志,2004,13(20):2690-2691.
6.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
7.赵晓民,侯伟,闫金玉,等.消癌平注射液治疗急性白血病6例[J]_中国中医急症,2007,16(1):105.
8.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J】.中国生化药物杂志,2007,28(4):247-250.
9.李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J】.中国生化药物杂志,2008,29(1):33-37.
10.王航宇,刘金荣,江发寿,等.新疆甘草多糖的超声提取及含量测定[J】.基层中药杂志,2001, 16(1):7-8.
11.Weber MM,Fottuer C,Liu SB,et al.Overexpression of the insulin-like growth factor Ⅰ receptor in human colon carcinomas[J].Cancer,2002,95(10):2086-2095.
1.中药大辞典编写组.中药大辞典[M】.上海:上海科技出版社,1993:470.
2.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,7:12-14.
3.李茂全,沈建华,胥彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
4.宋翠萍.消癌平注射液联合化疗治疗中晚期非小细胞肺癌36例[J].中医杂志,2008,49(6):494.
5.王文义,徐杨.消癌平治疗化疗失败后胃肠道肿瘤的疗效观察[J].肿瘤基础与临床,2008,21(8):356-357.
6.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
7.李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J】.中国生化药物杂志,2008,29(1):33-37.
8.赵晓民,侯伟,闰金玉,等.消癌平注射液治疗急性白血病6例[J].中国中医急症,2007,16(1):105.
9.Nicoletti I,Migliorati G,Pagliacci MC,et al.A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry[J].J Immunol Methods,1991,139(2):271-279.
10.Schwarz M,Andrade-Navarro MA,Gross A.Mitochondrial carders and pores:key regulators of the mitochondrial apoptotic program[J].Apoptosis,2007,12(5):869- 876.
11.MacLachlan TK,El-Deity WS.Apoptotic threshold is lowered by p53 transactivation of caspase-6[J].Proc Natl Acad Sci USA,2002,99(14):9492-9497.
1.绳娟,洪铁.11种中药对小鼠淋巴细胞活性及腹腔巨噬细胞功能的影响[J】.时珍国医国药,2007,18(2):390-392
2.郑志竑,林玲.神经细胞的培养与理论与实践,第1版[M】.北京:科学出版社,2002:194.
2.郑志竑,林玲.神经细胞的培养与理论与实践,第1版[M].北京:科学出版社,2002:194.
3.薛庆善,肖渝平,林娟.体外培养的原理与技术[M].北京:科学出版社,2001:561-564.
4.周丽娟,许利平.中药抗炎免疫药理免疫调节研究进展[J].中国中医基础医学杂志,2004,10(7):79-81.
5.储岳峰,颜新敏,胡元亮,等.几种中药成分的免疫增强活性及其作用效果[J].中国兽医科技,2005,35(1):67-70.
6.倪峰.免疫活性的中药多糖[J].福建中医学院学报,2001,11(1):5.
7.严林.冬虫夏草的药理研究进展[J].青海医学院学报,2000,21(4):37-38.
8.章梅,夏天,张仲海,等.四君子汤对脾虚患者血浆细胞因子的影响[J].第四军医大学学报,2001,21(4):411-413.
[1]Fidler IJ.Regulation of neoplastic angiogenesis.J Natl Cancer Inst Monogr,2001,28:10-14.
[2]Fidler IJ.Angiogenesis and cancer metastasis.Cancer J,2000,6(suppl 2):S134-141
[3]Folkman J.Angiogenesis inhibitors:a new class of drugs.Cancer Biol Ther,2003,2(suppl 1):S127-133.
[4]Kabbinavar FF,Hambleton J,Mass RD,et al.Combined analysis of efficacy:the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.J Clin Oncol,2005,23:3706-3712.
[5]Ansiaux R,Baudelet C,Jordan BF,et al.Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.Clin Cancer Res,2005,11:743-750.
[6]Ergun A,Camphausen K,Wein LM.Optimal scheduling of radiotherapy and angiogenic inhibitors.Bull Math Biol,2003,65:407-424.
[7]Koukourakis MI,Giatromanolaki A,Sivridis E,et al.Squamous cell head and neck cancer:evidence of angiogenic regeneration during radiotherapy.Anticancer Res,2001,21:4301-4309.
[8]Ma BB,Bristow RG,Kim J,et al.Combined-modality treat ment of solid tumors using radiotherapy and molecular targeted agents.J Clin Oncol,2003,21:2760-2776.
[9]Folkman J.Fundamental concepts of the angiogenic process.Curr Mol Med 2003;3:643-651.
[10]Hendrix MJC,Seftor EA,Hess AR,et al.Vasculogenic mimicry and tumor-cell plasticity:lessons from melanoma.Nat Rev Cancer,2003,3:411-421.
[11]Folkman J.How is blood vessel growth regulated in normal and neoplastic tissue G.H.A.Clowes Memorial Award Lecture.Cancer Res,1986,46:467-473.
[12]Fidler IJ,Ellis LM.The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 1994, 79:185-188.
[13]Liotta LA, Steeg PS, Stetler-Stevenson WG.Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991. 64:327-336.
[14] Kumar R, Yoneda J, Bucana CD,et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules.Int J Oncol, 1998, 12:749-757.
[15]Folkman J, Klagsbrun M. Angiogenic factors. Science, 1987, 235:442-447.
[16]Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst, 2001, 93:1040-1041.
[17]Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2002,2:727-739.
[18]Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.Lancet Oncol, 2001, 2:667-673.
[19]Niklinska W, Burzykowski T, Chyczewski L,et al. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.Lung Cancer, 2001, 34(suppl 2):S59-S64.
[20]Sugarbaker EV. Cancer metastasis: a product of tumor-host interactions. Curr Probl Cancer, 1979,3:1-59.
[21]Hart IR, Goode NT, Wilson RE.Molecular aspects of the metastatic cascade.Biochim Biophys Acta,1989, 989:65-84.
[22]Liotta LA, Stetler-Stevenson WG.Tumor invasion and metastasis: an imbalance of positive and negative regulation.Cancer Res, 1991, 51(suppl 18):S5054-5059.
[23]Singh RP, Agarwal R. Tumor angiogenesis: a potential target in cancer control by phytochemicals.Curr Cancer Drug Targets, 2003, 3:205-217.
[24] Jung YD, Ahmad SA, Akagi Y, et al.Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev, 2000, 19:147-157.
[25]Gutman M, Singh RK, Xie K, et al. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res, 1995, 55:2470-2475.
[26]Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth.. Nature, 1990, 348:555-557.
[27]Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest., 2000, 105:1045-1047.
[28]Maraveyas A, Lam T, Hetherington JW, Greenman J. Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer, 2005, 92:1588-1590
[29]Singh NP, Lai HC. Artemisinin induces apoptosis in human cancer cells. Anticancer Res, 2004,24:2277-2280.
[30]Chen HH, Zhou HJ, Wu GD,et al.Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/FLK-1. Pharmacology, 2004,7:1-9.
[31]Aldieri E, Atragene D, Bergandi L, et al. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett, 2003, 552:141-144.
[32]Liu JJ, Huang TS, Cheng WF,et al. Baicalein and baicalin are potent inhibitors of angiogenesis: inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer, 2003,106:559-565.
[33]Miocinovic R, McCabe NP, Keck RW, et al. In vivo and in vitro effect of baicalein on human prostate cancer cells.Int J Oncol., 2005, 26:241-246.
[34]Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting betacatenin-mediated transactivation and cell-cell adhesion pathways. J Mol Histol,2004, 35:301-307.
[35]Sen S, Sharma H, Singh N. Curcumin enhances vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun, 2005, 331:1245-1252.
[36]Khafif A, Hurst R, Kyker K, et al. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg, 2005, 132: 317-321.
[37]Shao ZM, Shen ZZ, Liu CH, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer, 2002, 98:234-240.
[38]Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med,1998, 4:376-383.
[39]Sreejayan Rao MN Nitric oxide scavenging by curcuminoids.J Pharm Pharmacol., 1997,49:105-107.
[40]Gururaj AE, Belakavadi M, Venkatesh DA, et al. Molecular mechanisms of antiangiogenic effect of curcumin. Biochem Biophys Res Commun, 2002,297:934-942.
[41]Shim JS, Kim JH, Cho HY, et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol, 2003, 10:695-704.
[42]Hahm ER, Gho YS, Park S et al. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem Biophys Res Commun, 2004, 321:337-344.
[43]Kim JH, Shim JS, Lee SK, et al. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J Cancer Res, 2002, 93:1378-1385.
[44]Dorai T, Cao YC, Dorai B, et al.Therapeutic potential of curcumin in prostate cancer. III: Curcumin inhibits proliferation, induces apoptosis and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.Prostate, 2001,47:293-303.
[45]Leu TH, Su SL, Chuang YC,et al. Direct inhibitory effect of curcumin on src and focal adhesion kinase activity.Biochem Pharmacol., 2003, 66:2323-2331.
[46]Cao Y, Fu ZD, Wang F,et al. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants.J Asian Nat Prod Res, 2005, 7:205-213.
[47]Igura K, Ohta T, Kuroda Y,et al. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett,2001, 171:11-16.
[48]Lin MT, Yen ML, Lin CY, et al.lnhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of src dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol., 2003, 64:1029-1036.
[49]Tseng SH, Lin SM, Chen JC, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res, 2004, 10:2190-2202.
[50]Singh RP, Tyagi AK, Dhanalakshmi S,et al. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer, 2004, 108:733-740.
[51]Khanna S, Roy S, Bagchi D, et al. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med, 2001, 31:38-42.
2.刘峰,麻柔.中西医临床血液病学(第1版)[M].北京:中国医药科技出版社,1998:244.
3.孙伟正,刘丽波,孙凤.中医血液病学(第1版)[M].北京:中国医药科技出版社,2000:104.
4.王东生,刘北忠.中药及其有效成分抗白血病的分子机制[J].国际中医中药杂志,2007,29(3):160-163.
5.唐由君.传统抗癌中成药配合中药复方治疗白血病的研究[J].中国中西医结合杂志,1998,18(10):583-584.
6.范先基,李俊,王志祥.王三虎治疗白血病的经验[J].广西中医药,2007,30(5):42-43.
7.邓有安,杨才明,谢波.活血化瘀中药联合化疗治疗急性白血病20例临床观察[J】.中国医药科技,2000,7(2):110-111
8.付亚玲,陈涛.中医药治疗白血病的研究现状[J].中西医结合学报,2008,6(8):867-872.
9.Yan C,Jamaluddin MS,Aggarwal B,et al.Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin[J].Mol Cancer Ther,2005,4(2):233-241.
10.王国俊,周黎明,王莉,等.三七皂甙R1诱导HL-60细胞凋亡的初步研究[J].四川生理科学杂志,2004,26(1):14-16.
11.陈婷梅,祝彼得.抗白血病中药及天然药物的研究现状[J].中国中西医结合杂志,1995,15(5):317-320.
12.花宝金.中药有效单体对肿瘤细胞诱导分化及凋亡的机制研究[J].中国中医基础医学杂志,2002,8(7):63-65.
13.Chen Y Y,Chang H M.Antiproliferative and differentiating effects of polysaccharide fraction from Fu-ling(Poria cocos) on human leukemic U937 and HL-60 cells[J].Food Chem Toxicol,2004,42(5):759-769.
14.张永清,黄高,刘红娟,等.苦参碱诱导K562细胞分化方向的研究[J].肿瘤学杂志,2004,10(1):25-27.
15.张谨,张洵,王永泉,等.藤黄酸对肿瘤细胞诱导分化作用的探讨[J].实用癌症杂志,2003,18(1):9-10.
16.陆羡,向金峰.β-榄香烯对K562细胞周期与细胞凋亡的影响及其机制探讨[J].中国小儿血液与肿瘤杂志,2008,13(4):149-152.
17.曲宝玺,纪运中,章萍,等.藤黄Ⅱ号对白血病L1210细胞杀伤动力学研究Ⅰ-显微分光光度计观察[J].中国肿瘤临床,1991(1):53-56.
18.林玲,吴周环,龚帧.中医药诱导分化白血病细胞凋亡研究进展[J].九江医学,2003,18(3):181-183.
19.王振义.开展砷剂治疗白血病的临床和机制的研究[J].中华血液学杂志,1996,7(2):57.
20.凌昌全,俞超芹,潘瑞萍,等.人参皂甙对人T淋巴细胞白血病细胞株凋亡基因的影响[J】.中医杂志,2000,41(3):176-177.
21.Suzuki K,Adachi R,Hirayama A,et al.Indirubin,a chinese anti-leukaemia drug,promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells[J].Br J Haematol,2005,130(5):681-690.
22.Tao Z,Zhou Y,Lu J,et al.Caspase-8 preferentially senses the apoptosis-inducing action of NG-18,a gmbogic acid derivative,in human leukemia HL-60 cells[J].Cancer Biol Ther,2007,6(5):691-696.
23.Liu J J,Wu X Y,Peng J,et al.Antiproliferation effects of oridonin on HL-60 cells[J].Ann Hematol,2004,83(11):691-695.
24.Liu J J,Huang R W,Lin D J,et al.Apoptotic effect of oridonin on NB4 cells and its mechanism [J].Leuk Lymphoma,2005,46(4):593-597.
25.Liu J J,Huang R W,Lin D J,et al.Oridonin-induced apoptosis in leukemia K562 cells and its mechanism[J].Neoplasma,2005,52(3):225-230.
26.高娜,茆俊卿,张育.中药逆转白血病多药耐药的研究进展[J].江苏中医药,2007,39(3):60-62.
27.谢长生,周维顺,冯正权,等.复方三根制剂对MDR细胞株K562/ADR和K562/VCR逆转作用的研究[J].中国实验方剂学杂志,2003,9(4):26-30.
28.高勇,王杰军,许青,等.人参皂甙Rg3抑制肿瘤新生血管形成机制研究[J】.肿瘤防治研究,2001,28(3):179-181.
29.姜晓玲.薏苡仁注射液对血管生成的影响[J】.肿瘤,2000,20(4):313.
30.Sohn K H,Lee H Y,Chung H Y,et al.Anti-angiogenesis activity of t riterpene acids[J].Cancer Lett,1995,94(2):213-217.
31.丁志山,高承贤,陈铌铍,等.姜黄素具有抑制血管生成与诱导肿瘤细胞凋亡双重作用[J】.中国药理学通报,2003,19(2):171-173.
32.陈志炉,史亦谦.中药诱导白血病细胞凋亡的研究近况[J].实用中西医结合临床,2007,7(3):91-93.
33.肖静云.免疫与正邪学说关系浅释[J].长春中医学院学报,2004,20(2):6.
34.马武开.中医药防治白血病的思路及方法[J].中国中医药信息杂志,2004,11(3):229-230
35.周锋,秦健,朱建中,等.莲必治注射液(穿心莲内酯)对免疫功能的调节作用(英文)[J】.南京医科大学学报(英文版),2004,18(1):40-43.
36.周金黄,刘干中.免疫药理学进展—基础与临床[M].北京:中国科学基础出版社,1993:367.
37.尹龙,徐亮,胡格,等.抗肿瘤中药及其有效成分的作用研究现状[J].动物医学进展,2006,27(1):39-43.
38.蔡文娥,杨斌.中药调节核因子-κB信号转导通路的研究进展[J].时珍国医国药,2006,17(9):1794-1796.
39.温志震,于宝海,魏虎来,等.白藜芦醇诱导K562细胞凋亡过程中Bcl-2蛋白水平的改变[J].中国临床药理学与治疗学,2006,11(4):421-423.
40.王甦,刘云鹏,候科佐,等.蟾蜍灵在诱导K562细胞凋亡过程中下调TOPO-Ⅱα蛋白表达[J].中华肿瘤防治杂志,2006,13(22):1701-1703.
41.刘加军,潘祥林,伍新尧,等.冬凌草甲素对Raji细胞的增殖抑制作用及其机制[J].中草药,2004,35(7):774-777.
42.王旭光,陈根殷,方琦.大蒜素对HL-60细胞端粒酶活性的影响.贵州医药,2004,28(4):303-305.
43.江苏新医学院.中药大辞典·下册[M].上海:上海人民出版社,1977:1976.
44.刘凤梧.中药学[M】.济南:山东科学技术出版社,1981:758.
45.蔡永敏.中药药名辞典[M].北京:中国医药出版社,1996:287
46.张民庆,龚惠明.抗癌中药的临床应用[M】.北京:人民卫生出版社,1998:100-101.
47.李红岩,王威,董方言.通光藤化学成分和药理作用研究进展[J】_中草药,2007,38(7):1101-1104.
48.Deng Jun,Liao Zhixin,Chen Dzofeng.Marsdenosides A-H,polyoxypregnane glycosides from Marsdenia Tenacissima.Phytochemistry,2005,66:1040-1051.
49.Luo Siqi,Long Longze,Geoffrey A.Polyoxypregnanes from Marsdenia Tenacissima. Phytochemistry,1993,34(6):1620-1651.
50.Shuji Miyakawa,Kimiko Yamaura,Koji Hayashi,et al.Five glycosides from the Chinese Drug "TONG-GUAN-TENG" the stem of Marsdenia Tenacissima.Phytochemistry,1986,25(12):2861-2865.
51.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J】.上海中医药杂志,2000,7(1):12-14.
52.李茂全,沈建华,胥彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
53.孙珏,沈建华,朱美华,等.消癌平对人胃癌细胞治疗作用的实验研究[J】.上海中医药大学学报,2000,14(2):41-43.
54.周丹,韩大庆,刘伟,等.消癌平片抗肿瘤作用研究[J].吉林中医药,2002,22(1):57-58.
55.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J】.中国民间疗法,2003,11(6):48.
56.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J】.上海医药,1996,(6):12-13.
57.孙珏,沈建华,朱美华,等.中药消癌平针剂经肝动脉介入治疗转移性肝癌的临床研究[J】.上海中医药杂志,2000,31(1):14-17.
58.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J】.现代中西医结合杂志,2004,13(20):2690-2691.
59.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J】.中国中西医结合杂志,2003,23(1):19-21.
60.赵素斌,王如美,李守霞.消癌平治疗原发性肝癌的临床疗效[J].邯郸医学高等专科学校学报,2005.18(5):415-416.
61.杨岷,吴静,李永强,等.消癌平注射液联合放疗治疗晚期非小细胞肺癌30例[J】.中医研究,2000,13(1):39-41.
62.赵晓民,侯伟,闫金玉,等.消癌平注射液治疗急性白血病6例[J】.中国中医急症,2007,16(1):105.
63.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J】.中国生化药 物杂志,2007,28(4):247-250.
64.李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J].中国生化药物杂志,2008,29(1):33-37.
65.李东,欧阳建,李翠萍,等.通关藤对U937细胞凋亡相关基因表达谱的影响[J】.中国生化药物杂志,2008,29(4):240-243.
1.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J】.上海中医药杂志,2000,7(1):12-14.
2.李茂全,沈建华,胥彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J】.介入放射学杂志,2001,10(4):228-231.
3.温建珍,郝青,杨玲.消癌平注射液治疗老年晚期消化道肿瘤57例[J].中国民间疗法,2003,11(6):48.
4.袁秀英,范忠泽,黄秀英.消癌平注射液治疗14例晚期胃癌的临床观察[J】.上海医药,1996,(6):12-13.
5.卢秋红,邓力.消癌平肝动脉灌注配合肝动脉栓塞化疗治疗肝癌的临床观察[J】.现代中西医结合杂志,2004,13(20):2690-2691.
6.王文荣,崔生达,曾黎明.中药消癌平配合超声引导经皮射频治疗中晚期肝癌的临床观察[J].中国中西医结合杂志,2003,23(1):19-21.
7.赵晓民,侯伟,闫金玉,等.消癌平注射液治疗急性白血病6例[J]_中国中医急症,2007,16(1):105.
8.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J】.中国生化药物杂志,2007,28(4):247-250.
9.李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J】.中国生化药物杂志,2008,29(1):33-37.
10.王航宇,刘金荣,江发寿,等.新疆甘草多糖的超声提取及含量测定[J】.基层中药杂志,2001, 16(1):7-8.
11.Weber MM,Fottuer C,Liu SB,et al.Overexpression of the insulin-like growth factor Ⅰ receptor in human colon carcinomas[J].Cancer,2002,95(10):2086-2095.
1.中药大辞典编写组.中药大辞典[M】.上海:上海科技出版社,1993:470.
2.孙珏,沈建华,朱美华,等.消癌平对人肝癌细胞治疗作用的实验研究[J].上海中医药杂志,2000,7:12-14.
3.李茂全,沈建华,胥彬,等.消癌平对SGC-7901胃癌细胞的作用及机制的实验研究[J].介入放射学杂志,2001,10(4):228-231.
4.宋翠萍.消癌平注射液联合化疗治疗中晚期非小细胞肺癌36例[J].中医杂志,2008,49(6):494.
5.王文义,徐杨.消癌平治疗化疗失败后胃肠道肿瘤的疗效观察[J].肿瘤基础与临床,2008,21(8):356-357.
6.李东,欧阳建,李翠萍,等.消癌平注射液对白血病细胞NB4作用的初步研究[J].中国生化药物杂志,2007,28(4):247-250.
7.李东,欧阳建,李翠萍,等.通关藤诱导白血病细胞U937,HL60细胞凋亡的实验研究[J】.中国生化药物杂志,2008,29(1):33-37.
8.赵晓民,侯伟,闰金玉,等.消癌平注射液治疗急性白血病6例[J].中国中医急症,2007,16(1):105.
9.Nicoletti I,Migliorati G,Pagliacci MC,et al.A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry[J].J Immunol Methods,1991,139(2):271-279.
10.Schwarz M,Andrade-Navarro MA,Gross A.Mitochondrial carders and pores:key regulators of the mitochondrial apoptotic program[J].Apoptosis,2007,12(5):869- 876.
11.MacLachlan TK,El-Deity WS.Apoptotic threshold is lowered by p53 transactivation of caspase-6[J].Proc Natl Acad Sci USA,2002,99(14):9492-9497.
1.绳娟,洪铁.11种中药对小鼠淋巴细胞活性及腹腔巨噬细胞功能的影响[J】.时珍国医国药,2007,18(2):390-392
2.郑志竑,林玲.神经细胞的培养与理论与实践,第1版[M】.北京:科学出版社,2002:194.
2.郑志竑,林玲.神经细胞的培养与理论与实践,第1版[M].北京:科学出版社,2002:194.
3.薛庆善,肖渝平,林娟.体外培养的原理与技术[M].北京:科学出版社,2001:561-564.
4.周丽娟,许利平.中药抗炎免疫药理免疫调节研究进展[J].中国中医基础医学杂志,2004,10(7):79-81.
5.储岳峰,颜新敏,胡元亮,等.几种中药成分的免疫增强活性及其作用效果[J].中国兽医科技,2005,35(1):67-70.
6.倪峰.免疫活性的中药多糖[J].福建中医学院学报,2001,11(1):5.
7.严林.冬虫夏草的药理研究进展[J].青海医学院学报,2000,21(4):37-38.
8.章梅,夏天,张仲海,等.四君子汤对脾虚患者血浆细胞因子的影响[J].第四军医大学学报,2001,21(4):411-413.
[1]Fidler IJ.Regulation of neoplastic angiogenesis.J Natl Cancer Inst Monogr,2001,28:10-14.
[2]Fidler IJ.Angiogenesis and cancer metastasis.Cancer J,2000,6(suppl 2):S134-141
[3]Folkman J.Angiogenesis inhibitors:a new class of drugs.Cancer Biol Ther,2003,2(suppl 1):S127-133.
[4]Kabbinavar FF,Hambleton J,Mass RD,et al.Combined analysis of efficacy:the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.J Clin Oncol,2005,23:3706-3712.
[5]Ansiaux R,Baudelet C,Jordan BF,et al.Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.Clin Cancer Res,2005,11:743-750.
[6]Ergun A,Camphausen K,Wein LM.Optimal scheduling of radiotherapy and angiogenic inhibitors.Bull Math Biol,2003,65:407-424.
[7]Koukourakis MI,Giatromanolaki A,Sivridis E,et al.Squamous cell head and neck cancer:evidence of angiogenic regeneration during radiotherapy.Anticancer Res,2001,21:4301-4309.
[8]Ma BB,Bristow RG,Kim J,et al.Combined-modality treat ment of solid tumors using radiotherapy and molecular targeted agents.J Clin Oncol,2003,21:2760-2776.
[9]Folkman J.Fundamental concepts of the angiogenic process.Curr Mol Med 2003;3:643-651.
[10]Hendrix MJC,Seftor EA,Hess AR,et al.Vasculogenic mimicry and tumor-cell plasticity:lessons from melanoma.Nat Rev Cancer,2003,3:411-421.
[11]Folkman J.How is blood vessel growth regulated in normal and neoplastic tissue G.H.A.Clowes Memorial Award Lecture.Cancer Res,1986,46:467-473.
[12]Fidler IJ,Ellis LM.The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 1994, 79:185-188.
[13]Liotta LA, Steeg PS, Stetler-Stevenson WG.Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 1991. 64:327-336.
[14] Kumar R, Yoneda J, Bucana CD,et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules.Int J Oncol, 1998, 12:749-757.
[15]Folkman J, Klagsbrun M. Angiogenic factors. Science, 1987, 235:442-447.
[16]Fidler IJ. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst, 2001, 93:1040-1041.
[17]Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2002,2:727-739.
[18]Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.Lancet Oncol, 2001, 2:667-673.
[19]Niklinska W, Burzykowski T, Chyczewski L,et al. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.Lung Cancer, 2001, 34(suppl 2):S59-S64.
[20]Sugarbaker EV. Cancer metastasis: a product of tumor-host interactions. Curr Probl Cancer, 1979,3:1-59.
[21]Hart IR, Goode NT, Wilson RE.Molecular aspects of the metastatic cascade.Biochim Biophys Acta,1989, 989:65-84.
[22]Liotta LA, Stetler-Stevenson WG.Tumor invasion and metastasis: an imbalance of positive and negative regulation.Cancer Res, 1991, 51(suppl 18):S5054-5059.
[23]Singh RP, Agarwal R. Tumor angiogenesis: a potential target in cancer control by phytochemicals.Curr Cancer Drug Targets, 2003, 3:205-217.
[24] Jung YD, Ahmad SA, Akagi Y, et al.Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev, 2000, 19:147-157.
[25]Gutman M, Singh RK, Xie K, et al. Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res, 1995, 55:2470-2475.
[26]Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth.. Nature, 1990, 348:555-557.
[27]Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest., 2000, 105:1045-1047.
[28]Maraveyas A, Lam T, Hetherington JW, Greenman J. Can a rational design for metronomic chemotherapy dosing be devised? Br J Cancer, 2005, 92:1588-1590
[29]Singh NP, Lai HC. Artemisinin induces apoptosis in human cancer cells. Anticancer Res, 2004,24:2277-2280.
[30]Chen HH, Zhou HJ, Wu GD,et al.Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/FLK-1. Pharmacology, 2004,7:1-9.
[31]Aldieri E, Atragene D, Bergandi L, et al. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett, 2003, 552:141-144.
[32]Liu JJ, Huang TS, Cheng WF,et al. Baicalein and baicalin are potent inhibitors of angiogenesis: inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer, 2003,106:559-565.
[33]Miocinovic R, McCabe NP, Keck RW, et al. In vivo and in vitro effect of baicalein on human prostate cancer cells.Int J Oncol., 2005, 26:241-246.
[34]Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting betacatenin-mediated transactivation and cell-cell adhesion pathways. J Mol Histol,2004, 35:301-307.
[35]Sen S, Sharma H, Singh N. Curcumin enhances vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun, 2005, 331:1245-1252.
[36]Khafif A, Hurst R, Kyker K, et al. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg, 2005, 132: 317-321.
[37]Shao ZM, Shen ZZ, Liu CH, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer, 2002, 98:234-240.
[38]Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med,1998, 4:376-383.
[39]Sreejayan Rao MN Nitric oxide scavenging by curcuminoids.J Pharm Pharmacol., 1997,49:105-107.
[40]Gururaj AE, Belakavadi M, Venkatesh DA, et al. Molecular mechanisms of antiangiogenic effect of curcumin. Biochem Biophys Res Commun, 2002,297:934-942.
[41]Shim JS, Kim JH, Cho HY, et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem Biol, 2003, 10:695-704.
[42]Hahm ER, Gho YS, Park S et al. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem Biophys Res Commun, 2004, 321:337-344.
[43]Kim JH, Shim JS, Lee SK, et al. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J Cancer Res, 2002, 93:1378-1385.
[44]Dorai T, Cao YC, Dorai B, et al.Therapeutic potential of curcumin in prostate cancer. III: Curcumin inhibits proliferation, induces apoptosis and inhibits angiogenesis of LNCaP prostate cancer cells in vivo.Prostate, 2001,47:293-303.
[45]Leu TH, Su SL, Chuang YC,et al. Direct inhibitory effect of curcumin on src and focal adhesion kinase activity.Biochem Pharmacol., 2003, 66:2323-2331.
[46]Cao Y, Fu ZD, Wang F,et al. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants.J Asian Nat Prod Res, 2005, 7:205-213.
[47]Igura K, Ohta T, Kuroda Y,et al. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett,2001, 171:11-16.
[48]Lin MT, Yen ML, Lin CY, et al.lnhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of src dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol., 2003, 64:1029-1036.
[49]Tseng SH, Lin SM, Chen JC, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res, 2004, 10:2190-2202.
[50]Singh RP, Tyagi AK, Dhanalakshmi S,et al. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer, 2004, 108:733-740.
[51]Khanna S, Roy S, Bagchi D, et al. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med, 2001, 31:38-42.